| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/22/2008 | US7402598 Arylethanolamine β2-adrenoreceptor agonist compounds |
| 07/22/2008 | US7402597 e.g. [[7-Allyl-3-[2-[2-(2,4-dichlorophenyl)-5-isopropyl-4-oxazolyl]ethyl]-1,2-benzisoxazol-6-yl]oxy]acetic acid; with vehicles (lactose, D-mannitol, glucose), disintegrators (starch or carboxymethylcellulose calcium ), binders (hydroxypropylcellulose) and lubricants (magnesium stearate or talc) |
| 07/22/2008 | US7402595 JNK inhibitor |
| 07/22/2008 | US7402591 Analgesic compositions containing buprenorphine |
| 07/22/2008 | US7402590 Spiroazacyclic compounds as monoamine receptor modulators |
| 07/22/2008 | US7402581 3,5-Dibromo-N-[(2S)-2-(4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-1-yl)butyl]-N-methylbenzamide; neurokinin 1 and 2 (NK1,2) receptors, antagonist; improved pharmacokinetics: not inhibit liver enzyme cytochrome P450, prevent drug-drug interactions, oral bioavailability, antiinflammatory and analgesic |
| 07/22/2008 | US7402580 Polymerase inhibitors; antiischemic agents; brain disorders; cardiovascular disorders; antiinflammatory agents; antiarthritic agents; neurodegenerative agents; Alzheimer's disease; muscular disorders; antidiabetic agents; kidney disorders; viricides; anticancer agents; immunosuppressants |
| 07/22/2008 | US7402578 Methods for inhibiting cognitive deterioration in adults with down's syndrome |
| 07/22/2008 | US7402563 EPF derived peptides and therapeutic compositions |
| 07/22/2008 | US7402560 oligopeptides capable of stimulating the proliferation or/and the outgrowth from cells presenting the neural cell adhesion molecule (NCAM), used for treatment of normal, degenerated and damaged NCAM presenting cells |
| 07/22/2008 | US7402406 Methods of evaluating phosphatase inhibitors |
| 07/22/2008 | US7402305 Comprises nucleotide sequences coding protein with antiproliferative and viricidal activity for use in treatment and prevention of cancer, nervous system, bone and autoimmune disorders |
| 07/22/2008 | US7402304 human granulocyte colony stimulating factor polypeptides having amino acid replacements in the sequence, used for treating hematopoietic, neurological or reproductive disorders |
| 07/22/2008 | US7402303 Chemokine mutants in the treatment of multiple sclerosis |
| 07/22/2008 | CA2384911C Method for the screening of .alpha.2. delta.-1 subunit binding ligands |
| 07/22/2008 | CA2383011C Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
| 07/22/2008 | CA2372840C Substituted bicyclic compounds |
| 07/22/2008 | CA2265095C Pyrazolopyrimidines and pyrazolotriazines |
| 07/22/2008 | CA2238171C Quinoline derivatives as nk3 antagonists |
| 07/22/2008 | CA2186673C The use of fatty acids in the treatment of huntington's chorea |
| 07/17/2008 | WO2008086483A2 Modulation of neurogenesis with use of modafinil |
| 07/17/2008 | WO2008086409A1 5-furopyridinone substituted indazoles |
| 07/17/2008 | WO2008086404A1 5-pyridinone substituted indazoles |
| 07/17/2008 | WO2008085567A1 Methods of using low-dose doxepin for the improvement of sleep |
| 07/17/2008 | WO2008085074A2 1, 3-dihydroimidazoles for treating cardiovascular disorders |
| 07/17/2008 | WO2008084962A1 THIAZOLE COMPOUND (AS PPARδ) LIGAND AND PHARMACEUTICAL, COSMETIC AND HEALTH FOOD COMPRISED THEREOF |
| 07/17/2008 | WO2008084873A1 Oxime derivative |
| 07/17/2008 | WO2008084864A1 Capsaicin receptor activator and apparatus for spraying the same |
| 07/17/2008 | WO2008084762A1 Neurogenesis-promoting composition comprising theanine |
| 07/17/2008 | WO2008084717A1 Tricyclic compound and pharmaceutical use thereof |
| 07/17/2008 | WO2008084504A2 Pharmaceutical compositions of angiotensin ii receptor blockers |
| 07/17/2008 | WO2008084492A1 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands |
| 07/17/2008 | WO2008084491A1 4-(heterocyclyl)alkyl-n-(arylsulfonyl) indole compounds and their use as 5-ht6 ligands |
| 07/17/2008 | WO2008084484A1 Psychotropic compounds, compositions and methods of use |
| 07/17/2008 | WO2008084483A1 Novel therapeutics based on tau/microtubule dynamics |
| 07/17/2008 | WO2008084324A1 Naphthyridinone compound |
| 07/17/2008 | WO2008084299A1 Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline |
| 07/17/2008 | WO2008084057A1 Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition |
| 07/17/2008 | WO2008084005A1 Spiropiperidine glycinamide derivatives |
| 07/17/2008 | WO2008083543A1 Nitrogen-containing heterocyclic modified compounds and uses thereof |
| 07/17/2008 | WO2008083442A1 Method for formulating combination medications for adhd |
| 07/17/2008 | WO2008063625A3 Pyridine compounds and methods of their use |
| 07/17/2008 | WO2008056257A3 Novel triazinedione derivatives as gaba-b receptor modulators |
| 07/17/2008 | WO2008020405A3 Azetidine compounds as orexin receptor antagonists |
| 07/17/2008 | WO2007073177A3 Composition comprising polyunsaturated fatty acids for improving membrane composition |
| 07/17/2008 | US20080171882 [(4S)-4-Methyl-2,5-dioxoimidazolidin-4-yl]methanesulfonyl chloride and [(4R)-4-methyl-2,5-dioxoimidazolidin-4-yl]methanesulfonyl chloride; chemical intermediates for enzyme inhibitors |
| 07/17/2008 | US20080171862 Double stranded RNA packaged in liposome for use therapeutic tool in treatment of cell proliferative and viral disorders; Antisense oligonucleotide for use in prevention and treatment of viral and tumor disorders; gene expression inhibition; RNA interference |
| 07/17/2008 | US20080171861 Method and medicament for inhibiting the expression of a given gene |
| 07/17/2008 | US20080171793 poly(imino-keto-methylene/amine) derivatives as a bioactive part in conjugates; diarrhea caused by pathogens: Vibrio cholerae, Clostridium difficile, Escherichia coli, Shigella, Salmonella, rotavirus; or enterotoxins: cholera toxin, E. coli toxin, Salmonella toxin |
| 07/17/2008 | US20080171789 Catechol protected levodopa diester prodrugs, compositions, and methods of use |
| 07/17/2008 | US20080171779 Use of 5-ht6 antagonists to prevent relapse into addiction |
| 07/17/2008 | US20080171777 Biaryl substituted triazoles as sodium channel blockers |
| 07/17/2008 | US20080171771 New Compounds 391 |
| 07/17/2008 | US20080171770 e.g. 2-(6,7-difluoro-1H-benzimidazol-1-yl)-N-{1-[4-(trifluoromethyl)phenyl]ethyl}aceta mide; vanilloid receptor 1 (VR1 or TRPV1) antagonist; antiinflammatory agent; neuropathic pain; arthritis, ischaemia, fibromyalgia, asthma, cough, inflammatory bowel disease, obesity |
| 07/17/2008 | US20080171755 4-(4-Benzo[1,3]dioxol-5-yl-1H-pyrazol-3-yl)-2-methylpyrimidine; affinity for activin receptor-like kinases 4/5; potent antagonists of these Transforming Growth Factor beta family type receptors; fibrosis; anticarcinogenic and -metastasis agents; demelination; expression inhibited by reducing signal path |
| 07/17/2008 | US20080171752 5-HT1A Receptor Subtype Agonist |
| 07/17/2008 | US20080171751 e.g., 2-tert-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-(1-methylcyclopropyl)-pyrimidine hydrochloride; central nervous system disorders; schizophrenia; antidepressant, anxiolytic agent, cognition activator; Parkinson's and Alzheimer's diseases |
| 07/17/2008 | US20080171750 Modulation Of Neurogenesis With Use of Modafinil |
| 07/17/2008 | US20080171737 Cyclic sulfonamide derivatives and methods of their use |
| 07/17/2008 | US20080171735 SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Abeta PROTEIN PRODUCTION |
| 07/17/2008 | US20080171733 Antiinflammatory agents, antidepressants, analgesics, purinergic receptor antagonists; neurodegenerative diseases, spinal cord injuries; 1-(2,3-dichlorophenyl)-N-[(2-methylphenyl)methyl]-1H-tetraazol-5-amine |
| 07/17/2008 | US20080171716 Nucleic acid modulation of toll-like receptor-mediated immune stimulation |
| 07/17/2008 | US20080171692 Substituted amides |
| 07/17/2008 | US20080171096 Method for Decreasing Nicotine and Other Substance Use in Humans |
| 07/17/2008 | US20080171080 Methods of treating neurological conditions with hematopoeitic growth factors |
| 07/17/2008 | US20080171065 Methods of Treating Nerve Entrapment Syndromes |
| 07/17/2008 | US20080171060 Lymphocyte receptor peptide for use in prevention and treatment of viral infection, cell proliferative, cardiovascular and allergic disorders; enhancing cytokine production |
| 07/17/2008 | US20080171055 Using blood brain barrier receptor specific immunoglobullin as diagnostic and therapeutic for prevention, detection treatment of brain disorders |
| 07/17/2008 | US20080171046 Novel proteins and nucleic acids encoding same |
| 07/17/2008 | US20080171036 Using tumor necrosis factor specific immuoglobulin for diagnosis, treatment and prevention of inflammatory, cell proliferative, skin, respiratory system, nervous system and infectious disorders |
| 07/17/2008 | US20080171021 Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
| 07/17/2008 | US20080170994 Diagnosis of brain disorders using antibodies capable of crossing the blood-brain barrier and reacting with the pathological substance; Alzheimer's disease, Parkinson's disease, Huntington's disease, bovine spongiform encephalopathy, West Nile virus encephalitis, brain or spinal cord injury, cancer |
| 07/17/2008 | CA2675132A1 Modulation of neurogenesis with use of modafinil |
| 07/17/2008 | CA2674958A1 Spiropiperidine glycinamide derivatives |
| 07/17/2008 | CA2674305A1 Therapy |
| 07/17/2008 | CA2674045A1 Tricyclic compound and pharmaceutical use thereof |
| 07/17/2008 | CA2673654A1 5-pyridinone substituted indazoles |
| 07/17/2008 | CA2673635A1 5-furopyridinone substituted indazoles |
| 07/17/2008 | CA2672190A1 4-(heterocyclyl)alkyl-n-(arylsulfonyl) indole compounds and their use as 5-ht6 ligands |
| 07/17/2008 | CA2671554A1 Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition |
| 07/16/2008 | EP1944306A1 Fused heterocyclic compounds as serotonin receptor modulators |
| 07/16/2008 | EP1944301A1 Novel benzoxathiin derivative |
| 07/16/2008 | EP1944298A1 Quinazoline derivative and pharmaceutical |
| 07/16/2008 | EP1944296A1 Amorphous phase of a substituted pyrazoline, its preparation and use as medicaments |
| 07/16/2008 | EP1944292A1 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents |
| 07/16/2008 | EP1944290A1 Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity |
| 07/16/2008 | EP1944289A1 Compounds which potentiate glutamate receptor and uses thereof in medicine |
| 07/16/2008 | EP1944041A1 Therapeutic agent for neurogenic pain |
| 07/16/2008 | EP1944035A1 Method for reducing pain using oncolytic viruses |
| 07/16/2008 | EP1944034A1 Adsorbent for advanced glycation endproducts |
| 07/16/2008 | EP1944031A1 use of ivabradine for the treatment of endothelial dysfunction |
| 07/16/2008 | EP1944030A1 Agent for treatment of schizophrenia |
| 07/16/2008 | EP1944022A1 Pharmaceutical compositions combining analgesics and anticonvulsant agents for the treatment of chronic and acute pain |
| 07/16/2008 | EP1943251A2 A1 adenosine receptor agonists |
| 07/16/2008 | EP1943250A1 Fused and spirocycle compounds and the use thereof |
| 07/16/2008 | EP1943244A1 Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors |
| 07/16/2008 | EP1943242A1 Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists |
| 07/16/2008 | EP1943230A2 Compounds which have activity at m1 receptor and their uses in medicine |
| 07/16/2008 | EP1943217A1 Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses |
| 07/16/2008 | EP1943216A1 Prolinamide derivatives as sodium channel modulators |